[Effect of recombinant human erythropoietin on the bone marrow picture in patients with chronic renal failure treated by hemodialysis].
The influence of recombinant human erythropoietin (rHu-EPO) on anaemia and bone marrow cells was investigated in 7 patients with terminal renal failure on maintenance haemodialysis. The examination was performed immediately prior to rHu-EPO treatment (mean hematocrit 20.3%) and after increase of hematocrit to 33%. An increased number of cells from the erythroblastic series and rejuvenation of this population were observed during the treatment. There was no significant influence of the treatment on the myeloblastic cells series. An increase in megakaryocyte activity was observed in 2 studied patients.
Sułowicz
W
W
Kliniki Nefrologii Akademii Medycznej im. M. Kopernika, Krakowie.
Hanicki
Z
Z
Skotnicki
A B
AB
Wójcik
J
J
Sydor
A
A
D000328:Adult; D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D001772:Blood Cell Count / Q000187:drug effects; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology*; D002452:Cell Count / Q000187:drug effects; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006400:Hematocrit; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis
D004921:Erythropoietin
Wpływ rekombinowanej ludzkiej erytropoetyny na obraz szpiku kostnego u chorych z przewlekła niewydolnościa nerek leczonych hemodializami.